A new scoring system for differentiating malignant from benign "second-look" breast lesions detected by MRI in patients with known breast cancer

AIM

To propose a scoring system made of reproducible and objective criteria to aid in differentiating malignant from benign "second-look" breast lesions detected at magnetic resonance imaging (MRI).

MATERIALS AND METHODS

Data were collected retrospectively for "second-look" lesions identified on breast MRI studies performed at the University Hospitals of Leicester NHS Trust breast unit over a 2-year period (from January 2020 to January 2022). Ninety-five "second look" MRI-detected lesions were included in this retrospective study. Lesions were assessed according to margins, T2 signal, internal enhancement patterns, contrast kinetics, and diffusion-weighted imaging (DWI) patterns.

RESULTS

Fifty-two per cent of the included lesions were confirmed at histopathology to be malignant. The most common contrast kinetics identified in malignant lesions was the plateau pattern followed by the washout pattern while the most common pattern in benign lesions was the progressive pattern. The apparent diffusion coefficient (ADC) cut-off value for separating benign and malignant lesions at the unit was found to be 1.1 × 10-3 mm2/s. Based on the MRI features described above, a scoring system is suggested to help differentiate benign from malignant "second-look" lesions. According to the present results, setting a score of 2 or more points as an indication for biopsy was 100% reliable in identifying malignant lesions and avoiding biopsies in >30% of lesions.

CONCLUSION

The suggested scoring system could avoid biopsy of >30% of the "second-look" lesions detected by MRI without missing any malignant lesions.

Pulmonary capillary hemangiomatosis: a case series and review of literature

Pulmonary capillary hemangiomatosis (PCH) is a rare cause of pulmonary hypertension (PH) of unknown etiology resulting from pulmonary capillary proliferation. Clinically, PCH is seen in young adults with equal sex predilection and rarely reported familial predisposition. PCH's main clinical presentations are progressive dyspnea, fatigue, hemoptysis, palpitations, and later irreversible pulmonary hypertension and right-sided heart failure. Hereby, we report three PCH cases, each case presented with a peculiar presentation with a comprehensive literature review highlighting etiology, clinical presentations, diagnostic modalities and pathology in establishing a diagnosis, current treatment options, and prognosis of PCH. In conclusion, defining PCH as the underlying cause of PH is of utmost importance as most medications used for PH are ineffective in PCH. Vasodilators should be avoided due to the increased risk of pulmonary oedema. Pathological examination of the lung is still considered the most definitive diagnostic tool, yet it is associated with complications risk. High-Resolution Computed Tomography (HRCT) chest is currently considered the cornerstone non-invasive modality for the diagnosis of PH. So far, no definitive treatment of PCH excluding lung transplantation with preliminary promising results with angiogenesis Inhibitors. PCH carries a very poor prognosis with a median survival of 3 years from the time of diagnosis.

A bilharzial pulmonary artery aneurysm with a large calcified mural thrombus

Although very rarely encountered nowadays, bilharziasis should still be considered as one of the main causes of pulmonary artery aneurysms (PAA) and core-pulmonale in endemic areas. The ideal treatment of PAA remains uncertain because there is no clear consensus about the best therapeutic approach, due to limited experience because of the rarity of the disease. Still the management of pulmonary artery thrombus is only through proper anticoagulation and follow-up with a very limited role for surgery.

Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment

OBJECTIVE

To assess the effectiveness of long term treatment with clopidogrel of patients with extracardiac vascular disease (ECVD) (a history of either peripheral arterial disease or cerebrovascular disease).

DESIGN

Subgroup analysis of a prospective randomised clinical trial.

SETTING

The CREDO (clopidogrel for the reduction of events during observation) trial was a randomised, double blind, placebo controlled trial conducted at 99 centres in North America from June 1999 through April 2001.

PATIENTS

2116 patients who were to undergo elective coronary intervention or were deemed at high likelihood of undergoing percutaneous coronary intervention were enrolled in the CREDO trial. The current study sample consisted of 272 patients with ECVD.

MAIN OUTCOME MEASURE

One year incidence of the composite of death, myocardial infarction, or stroke in the intent to treat population.

RESULTS

Patients with ECVD had a more than twofold greater relative risk reduction with clopidogrel for the primary end point compared with patients without ECVD (47.9%, 95% confidence interval (CI) -4.2% to 73.9%, v 18.2%, 95% CI -10.5 % to 39.5%, respectively).

CONCLUSIONS

Longer term clopidogrel treatment provides added protection against thrombotic events throughout the arterial vasculature, not limited to the coronary arteries, and may be especially effective for patients with more diffuse atherosclerosis such as ECVD.